Decentralized Clinical Trials (DCTs) provide pharmaceutical companies with various benefits, including cost savings, improved patient recruitment and retention, flexible operations, and better data quality. While the technology and data to support DCTs existed before the pandemic, only a few pilots were conducted.
Today, the need for remote patient- and site-centric trials has led to increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate, indicating that DCTs are a lasting trend. Additionally, advances in technology, innovative business models, increased wearables support, regulatory bodies’ push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape.
In this report, we analyze the current state of the DCT market and deep dive into its adoption, market trends, DCT platform providers’ landscape, enterprise view of DCT platform providers, Environment, Social, and Governance (ESG) initiatives, and emerging technology opportunities in the industry.
Scope
Industry: life sciences
Geography: global
Contents
In this report, we:
- Study DCT adoption trends and market dynamics
- Examine the DCT platform provider landscape
- Provide an enterprise view of DCT providers
- Analyze ESG initiatives and emerging technology opportunities in the industry
Membership(s)
Life Sciences Information Technology
Sourcing and Vendor Management
